Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APV006
- Development stage
- Phase 1
- Lead developer
- LG Chem
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
APV006 is a hexavalent (6-in-1) vaccine candidate developed by LG Chem to protect infants against six infectious diseases: diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b (Hib) infection. The vaccine is formulated with an acellular pertussis (DTaP) component, distinguishing it from LG Chem's other hexavalent candidate, LBVD, which utilizes a whole-cell pertussis component. By combining multiple antigens into a single injection, APV006 aims to simplify immunization schedules and improve compliance. It is currently in early-stage clinical development, with Phase I trials evaluating its safety and immunogenicity in healthy adults. LG Chem plans to commercialize the vaccine in South Korea by 2030 following further clinical development and the construction of dedicated manufacturing facilities.
- Other names
- DTaP-HepB-IPV-Hib vaccineLG Chem hexavalent vaccine
02
Targets
Diphtheria toxinHBsAg (Hepatitis B surface antigen)PRR (Pattern recognition receptors)PV3 (Sabin) (Poliovirus type 3 antigen)FHA (Filamentous hemagglutinin)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on APV006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APV006.